Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation - Summary - MDSpire
Advertisement
Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation
To evaluate the dermatologic safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to dipeptidyl peptidase-4 inhibitors (DPP-4is) in individuals with type 2 diabetes.
Key Findings:
GLP-1 RA initiation was associated with a higher risk of incident psoriasis (HR 1.19, 95% CI 1.11–1.28).
GLP-1 RAs were linked to lower risks of pemphigus (HR 0.32, 95% CI 0.16–0.63) and bullous pemphigoid (HR 0.61, 95% CI 0.43–0.87).
No significant differences were observed for other inflammatory or autoimmune skin outcomes after multiple-testing correction.
Interpretation:
GLP-1 RAs may increase the risk of psoriasis while decreasing the risk of certain autoimmune blistering diseases compared to DPP-4is, suggesting a differential dermatologic safety profile.
Limitations:
Observational study design may introduce residual confounding.
Findings are based on real-world data, which may not capture all relevant clinical variables.
Conclusion:
GLP-1 RAs are associated with increased psoriasis and decreased autoimmune blistering diseases compared to DPP-4is, highlighting the need for ongoing skin monitoring in patients receiving incretin therapy.
